- Home
- CMMB vs GIGM Comparison
CMMB vs GIGM Comparison
Compare CMMB & GIGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- GIGM
- Stock Information
- Founded
- CMMB 2004
- GIGM 1998
- Country
- CMMB Israel
- GIGM Taiwan
- Employees
- CMMB N/A
- GIGM N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- GIGM Computer Software: Programming Data Processing
- Sector
- CMMB Health Care
- GIGM Technology
- Exchange
- CMMB Nasdaq
- GIGM Nasdaq
- Market Cap
- CMMB 22.0M
- GIGM 17.0M
- IPO Year
- CMMB N/A
- GIGM 2000
- Fundamental
- Price
- CMMB $3.03
- GIGM $1.81
- Analyst Decision
- CMMB Strong Buy
- GIGM
- Analyst Count
- CMMB 2
- GIGM 0
- Target Price
- CMMB $26.50
- GIGM N/A
- AVG Volume (30 Days)
- CMMB 143.6K
- GIGM 21.4K
- Earning Date
- CMMB 08-14-2025
- GIGM 10-29-2025
- Dividend Yield
- CMMB N/A
- GIGM N/A
- EPS Growth
- CMMB N/A
- GIGM N/A
- EPS
- CMMB N/A
- GIGM N/A
- Revenue
- CMMB N/A
- GIGM $3,250,000.00
- Revenue This Year
- CMMB N/A
- GIGM N/A
- Revenue Next Year
- CMMB N/A
- GIGM N/A
- P/E Ratio
- CMMB N/A
- GIGM N/A
- Revenue Growth
- CMMB N/A
- GIGM N/A
- 52 Week Low
- CMMB $2.96
- GIGM $1.30
- 52 Week High
- CMMB $9.84
- GIGM $1.87
- Technical
- Relative Strength Index (RSI)
- CMMB 26.72
- GIGM 71.65
- Support Level
- CMMB $2.96
- GIGM $1.61
- Resistance Level
- CMMB $3.14
- GIGM $1.87
- Average True Range (ATR)
- CMMB 0.22
- GIGM 0.09
- MACD
- CMMB 0.01
- GIGM 0.03
- Stochastic Oscillator
- CMMB 8.09
- GIGM 86.12
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.